Zelenskiy, Allies Set to Plead With Trump to Stand Behind Ukraine
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Novo Nordisk, Eli Lilly rise after Viking obesity trial data
-- Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics' Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment. Novo Nordisk (NYSE:NVO) rose 1.4% premarket, while Eli Lilly gained 1.2%. Viking Therapeutics (NASDAQ:VKTX) plunged over 30% in premarket trading. The trial tested Viking's oral tablet VK2735, a dual GLP-1 and GIP receptor agonist, and met its primary endpoint, with patients losing up to 12.2% of body weight after 13 weeks versus 1.3% for placebo. However, a 28% treatment discontinuation rate among VK2735 recipients raised concerns, compared with 18% in the placebo group. Viking said 99% of gastrointestinal-related adverse events were mild or moderate, and an exploratory maintenance dosing arm indicated weight loss could be maintained at lower doses. Mizuho analyst Jared Holz said the data highlighted challenges relative to Eli Lilly's offerings. 'Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range — but over 72-weeks; a much longer trial, and therefore LLY looks far better head-to-head,' Holz wrote. He added that Viking would likely need pipeline improvements or enhanced formulations to regain investor interest. 'A tough day for retail investors ahead – that have been pumping this thing like a 1991 Reebok Dee Brown," concluded Holz. The results underscore the competitive pressure in the oral obesity market. Related articles Novo Nordisk, Eli Lilly rise after Viking obesity trial data Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025
Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For those of you who have signed up, we look forward to seeing you at the event. The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session. A link for the webcast of the plenary sessions will be available on our website closer to the date. The purpose of the event is to give institutional investors and financial analysts an introduction to the new 5-year strategy for the company, as well as to provide the opportunity to meet with the broader Management team. The day will start with a plenary session, covering the introduction of the new Group strategy, a financial update, and the strategy for the Chronic Care businesses. In the afternoon, participants will be split into groups and rotate between four Q&A breakout sessions. Participation in the breakout sessions will be in-person only (with a replay of the presentations available after the event). The formal program will end at 17.00, followed by an opportunity to meet the Coloplast management team in an informal setting. Agenda in CEST10.00 - 10.30 Registration10.30 - 12.30 Plenary session: Group strategy and financials, Chronic Care Commercial strategy12.30 - 13.00 Lunch break13.00 - 17.00 Q&A breakout sessions (incl. breaks)17.00 - 18.30 Social activity (on premise) Coloplast representatives Plenary session: Lars Rasmussen, Interim President and CEO Anders Lonning-Skovgaard, Executive Vice President, CFO Caroline Vagner Rosenstand, Executive Vice President, Chronic Care Commercial Breakout sessions: Chronic Care deep dive: Mike DelVacchio, Senior Vice President, North America Thomas Bruhn, Senior Vice President, Emerging Markets Wound & Tissue Repair: Fertram Sigurjonsson, Executive Vice President, Wound & Tissue Repair Bernd Greiner, Senior Vice President, Adv. Wound Dressings Interventional Urology: Thomas NP Johns Jr, Executive Vice President, Interventional Urology Global Operations and People & Culture: Allan Rasmussen, Executive Vice President, Global Operations Dorthe Rønnau, Executive Vice President, People & Culture * For more information,please contact: Aleksandra Dimovska, Vice PresidentDirect tel.: +45 4911 2458E-mail: dkadim@ Kristine Husted Munk, Sr. ManagerDirect tel.: +45 4911 3266E-mail: dkkhu@ Simone Dyrby Helvind, Sr. Manager Direct tel.: +45 4911 2981E-mail: dksdk@ Julie Sommer Müggler, Coordinator Direct tel.: +45 4911 3161Email: dkjusm@ Attachment Updated presenters list Coloplast CMD 2025
Yahoo
9 minutes ago
- Yahoo
Bessent: U.S. won't force to buy Intel chips, investment to help stabilize
-- U.S. Treasury Secretary Scott Bessent clarified Tuesday that any potential government investment in Intel (NASDAQ:INTC) would aim to stabilize the chipmaker rather than artificially boost its business. When asked about reports suggesting the U.S. government might take a 10% stake in Intel, Bessent told CNBC: "The last thing we're going to do is take a stake and then try to drum up business. The stake would be a conversion of the grants and maybe increase the investment into Intel to help stabilize the company for chip production here in the U.S. There's no talk of trying to force companies to buy from Intel." Bessent did not provide specific details about the size or timing of any potential U.S. government stake in the company. His comments came just one day after SoftBank (TYO:9984) Group agreed to invest $2 billion in Intel, which has faced challenges competing in the market following years of management missteps. Related articles Bessent: U.S. won't force to buy Intel chips, investment to help stabilize If Powell goes, does Fed trust go with him? 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Sign in to access your portfolio
